Oct 27, 2025 06:53AM Wedbush Upgrades Fate Therapeutics (FATE) to Outperform

Oct 27, 2025 12:29AM Fate Therapeutics presents lupus trial data showing patient responses

Sep 3, 2025 06:20AM Fate Therapeutics (FATE) PT Lowered to $7 at Leerink Partners

Aug 13, 2025 05:24AM Fate Therapeutics (FATE) PT Lowered to $2.50 at Wells Fargo

Aug 12, 2025 05:31PM Fate Therapeutics (FATE) Tops Q2 EPS by 5c

Jul 2, 2025 06:39AM H.C. Wainwright Reiterates Neutral Rating on Fate Therapeutics (FATE)

Jun 12, 2025 07:25AM Needham Reiterates Hold Rating on Fate Therapeutics (FATE)

Jun 11, 2025 01:00PM Fate Therapeutics (FATE) PT Lowered to $2.20 at BofA Securities

Jun 11, 2025 09:02AM Fate Therapeutics (FATE) Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis

May 30, 2025 04:30PM Fate Therapeutics (FATE) names Matthew Abernethy to Board

May 28, 2025 05:55PM Fate Therapeutics (FATE) announces phase 1 data presentation on FT819

May 14, 2025 04:30AM Fate Therapeutics (FATE) PT Lowered to $4 at Baird

May 13, 2025 06:12PM Fate Therapeutics (FATE) Tops Q1 EPS by 7c

Apr 14, 2025 08:01AM Fate Therapeutics (FATE) Receives RMAT Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus

Mar 6, 2025 09:54AM Fate Therapeutics (FATE) PT Lowered to $3 at Stifel

Mar 6, 2025 05:19AM Fate Therapeutics (FATE) PT Lowered to $8 at Jefferies

Mar 5, 2025 04:53PM Fate Therapeutics (FATE) Reports In-Line Q4 EPS

Jan 2, 2025 04:00PM Biotech outlook for 2025: Stifel

Dec 9, 2024 04:02PM Fate Therapeutics (FATE) Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Nov 29, 2024 01:05PM Fate Therapeutics (FATE) announces Scott Wolchko, President and CEO, will retire effective December 31

Nov 18, 2024 03:49PM BofA Securities Upgrades Fate Therapeutics (FATE) to Neutral, 'Following initial autoimmune clinical data presented at ACR Convergence'

Nov 18, 2024 02:11PM Oppenheimer Reiterates Perform Rating on Fate Therapeutics (FATE)

Nov 18, 2024 01:31PM Stifel Reiterates Hold Rating on Fate Therapeutics (FATE)

Nov 18, 2024 11:22AM TD Cowen Reiterates Hold Rating on Fate Therapeutics (FATE)

Nov 18, 2024 08:05AM Fate Therapeutics (FATE) Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study

Nov 13, 2024 08:53AM Fate Therapeutics (FATE) PT Lowered to $5 at BMO Capital

Nov 12, 2024 09:22PM Fate Therapeutics (FATE) Tops Q3 EPS by 2c

Aug 14, 2024 02:05PM TD Cowen Reiterates Hold Rating on Fate Therapeutics (FATE)

Aug 14, 2024 10:08AM BMO Capital Reiterates Market Perform Rating on Fate Therapeutics (FATE)

Aug 14, 2024 08:37AM Fate Therapeutics (FATE) PT Lowered to $5 at Stifel

Aug 14, 2024 08:23AM Piper Sandler Reiterates Overweight Rating on Fate Therapeutics (FATE)

Aug 13, 2024 05:07PM Fate Therapeutics (FATE) Tops Q2 EPS by 13c

Aug 13, 2024 05:07PM Fate Therapeutics (FATE) Tops Q2 EPS by 13c

Jul 31, 2024 08:03AM Fate Therapeutics (FATE) Appoints Neely Mozaffarian to its Board

Jun 17, 2024 03:50AM Piper Sandler Upgrades Fate Therapeutics (FATE) to Overweight